{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T15:21:13Z","timestamp":1778685673175,"version":"3.51.4"},"reference-count":22,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"\n Importance<\/jats:title>\n Patients with heart failure (HF) and mildly reduced ejection fraction (HFmrEF) or preserved EF (HFpEF) show substantial heterogeneity in prognosis.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n To evaluate the performance of biomarker-driven prognostic models derived from the Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction (EMPEROR-Preserved) Trial in the Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure (FINEARTS-HF) and to examine whether baseline risk modified the therapeutic effect of finerenone.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This is a prespecified secondary analysis of the FINEARTS-HF trial, which was conducted across 653 sites in 37 countries among adults aged 40 years and older with symptomatic HF and left ventricular EF (LVEF) of 40% or greater. Patients were randomized between September 2020 and January 2023, and data analysis for this study was conducted from September to October 2025. The median (IQR) follow-up period was 32 (23-37) months.<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n Finerenone (titrated to 20 mg or 40 mg) or placebo.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n EMPEROR-Preserved risk scores for the outcomes of first HF hospitalization or cardiovascular death, cardiovascular death, and all-cause death were calculated in FINEARTS-HF using models incorporating N-terminal pro-B-type natriuretic peptide, high-sensitivity cardiac troponin T, New York Heart Association functional class, history of chronic obstructive pulmonary disease and diabetes, insulin use, and\u2014depending on outcome\u2014age, hemoglobin and albumin levels, HF duration, time from prior HF hospitalization, and sodium-glucose transporter 2 inhibitor use. Estimated risks were compared with observed event rates, and model performance was assessed using Harrell C statistic. Treatment effects were evaluated across risk quintiles (Q1 to Q5) and across the continuous risk distribution.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among 6001 patients (mean [SD] age, 72.0 [9.6] years; 2732 [45.5%] women; 3003 randomized to finerenone and 2998 randomized to placebo), the EMPEROR-Preserved risk model estimated risk of outcomes, with Q5 vs Q1 hazard ratios (HRs) of 10.49 (95% CI, 8.14-13.52) for the composite of HF hospitalization or cardiovascular death and 13.47 (95% CI, 8.79-20.64) for cardiovascular death. The model demonstrated good discrimination. The treatment effect of finerenone was consistent across risk quintiles for first HF hospitalization or cardiovascular death (Q1: HR, 0.93 [95% CI, 0.58-1.49]; Q2: HR, 1.04 [95% CI, 0.76-1.43]; Q3: HR, 0.82 [95% CI, 0.62-1.07]; Q4: HR, 0.81 [95% CI, 0.65-1.01]; and Q5: HR, 0.88 [95% CI, 0.74-1.05];\n P<\/jats:italic>\n for interaction\u2009=\u2009.68) and remained uniform across the continuous risk spectrum.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n The EMPEROR-Preserved risk models demonstrated good performance in FINEARTS-HF. Baseline risk did not modify the relative treatment effect of finerenone.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT04435626<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamacardio.2026.1049","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T19:30:19Z","timestamp":1774726219000},"page":"416","source":"Crossref","is-referenced-by-count":0,"title":["EMPEROR-Preserved Risk Model and Outcomes in the FINEARTS-HF Trial"],"prefix":"10.1001","volume":"11","author":[{"given":"Misato","family":"Chimura","sequence":"first","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom"},{"name":"Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsty","family":"McDowell","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pardeep S.","family":"Jhund","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alasdair D.","family":"Henderson","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian L.","family":"Claggett","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akshay S.","family":"Desai","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meike","family":"Brinker","sequence":"additional","affiliation":[{"name":"Bayer AG, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Lay-Flurrie","sequence":"additional","affiliation":[{"name":"Bayer AG, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Glasauer","sequence":"additional","affiliation":[{"name":"Bayer AG, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Goea","sequence":"additional","affiliation":[{"name":"Bayer AG, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Berger","sequence":"additional","affiliation":[{"name":"Bayer AG, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn S. P.","family":"Lam","sequence":"additional","affiliation":[{"name":"National Heart Centre Singapore & Duke-National University of Singapore, Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Senni","sequence":"additional","affiliation":[{"name":"University of Milano-Bicocca, Papa Giovanni XXIII Hospital, Bergamo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriaan A.","family":"Voors","sequence":"additional","affiliation":[{"name":"University Medical Center Groningen, Groningen, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"Inserm Clinical Investigation Centre, Universit\u00e9 de Lorraine, CHU, Nancy, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Michigan, Ann Arbor"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J. V.","family":"McMurray","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"10","key":"hoi260023r1","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrcardio.2017.65","article-title":"Epidemiology of heart failure with preserved ejection fraction.","volume":"14","author":"Dunlay","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"hoi260023r2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2024.132304","article-title":"Heart failure with preserved ejection fraction epidemiology, pathophysiology, diagnosis and treatment strategies.","volume":"412","author":"Abdin","year":"2024","journal-title":"Int J Cardiol"},{"issue":"18","key":"hoi260023r3","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/j.jacc.2023.01.049","article-title":"Heart failure with preserved ejection fraction: JACC scientific statement.","volume":"81","author":"Borlaug","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"hoi260023r4","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1186\/s12913-022-08614-x","article-title":"Healthcare resource utilization and costs among patients with heart failure with preserved, mildly reduced, and reduced ejection fraction in Spain.","volume":"22","author":"Escobar","year":"2022","journal-title":"BMC Health Serv Res"},{"issue":"7","key":"hoi260023r5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2024.101025","article-title":"The societal burden of heart failure with preserved or mid-range ejection fraction.","volume":"3","author":"Weintraub","year":"2024","journal-title":"JACC Adv"},{"issue":"6","key":"hoi260023r6","doi-asserted-by":"publisher","first-page":"4104","DOI":"10.1002\/ehf2.15008","article-title":"Systematic review and meta-analysis to predict mortality in heart failure with preserved ejection fraction: development and validation of the HF-DANAS score.","volume":"11","author":"Wang","year":"2024","journal-title":"ESC Heart Fail"},{"issue":"9","key":"hoi260023r7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0332913","article-title":"A novel risk score model for predicting mortality in heart failure with preserved ejection fraction: insights from the CURE-HF Registry-ApHAC score.","volume":"20","author":"Aoki","year":"2025","journal-title":"PLoS One"},{"issue":"20","key":"hoi260023r8","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.009594","article-title":"Meta-Analysis Global Group in Chronic (MAGGIC) heart failure risk score: validation of a simple tool for the prediction of morbidity and mortality in heart failure with preserved ejection fraction.","volume":"7","author":"Rich","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"hoi260023r9","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1002\/ejhf.2607","article-title":"Biomarker-driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.","volume":"24","author":"Pocock","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"16","key":"hoi260023r10","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction.","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"16","key":"hoi260023r11","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction.","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"hoi260023r12","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/ejhf.3253","article-title":"Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: rationale and design of the FINEARTS-HF trial.","volume":"26","author":"Vaduganathan","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"hoi260023r13","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/ejhf.3266","article-title":"Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: the FINEARTS-HF trial.","volume":"26","author":"Solomon","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"hoi260023r14","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.jchf.2021.04.009","article-title":"Integrating high-sensitivity troponin T and sacubitril\/valsartan treatment in HFpEF: the PARAGON-HF trial.","volume":"9","author":"Gori","year":"2021","journal-title":"JACC Heart Fail"},{"key":"hoi260023r15","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/1467-9868.00259","article-title":"Semiparametric regression for the mean and rate functions of recurrent events.","volume":"62","author":"Lin","year":"2000","journal-title":"J R Stat Soc Series B Stat Methodol"},{"issue":"5","key":"hoi260023r16","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1001\/jamacardio.2024.0284","article-title":"Prognostic models for mortality and morbidity in heart failure with preserved ejection fraction.","volume":"9","author":"McDowell","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"6","key":"hoi260023r17","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1001\/jamacardio.2025.0025","article-title":"Finerenone for heart failure and risk estimated by the PREDICT-HFpEF Model: a secondary analysis of FINEARTS-HF.","volume":"10","author":"McDowell","year":"2025","journal-title":"JAMA Cardiol"},{"issue":"10","key":"hoi260023r18","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1002\/ejhf.2346","article-title":"Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC).","volume":"23","author":"Meijers","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"hoi260023r19","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1161\/CIRCULATIONAHA.111.044149","article-title":"Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials.","volume":"125","author":"Masson","year":"2012","journal-title":"Circulation"},{"issue":"10","key":"hoi260023r20","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1002\/ejhf.414","article-title":"Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction.","volume":"17","author":"Sanders-van Wijk","year":"2015","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"hoi260023r21","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.jchf.2024.12.010","article-title":"Effects of sacubitril\/valsartan according to natriuretic peptide levels in patients enrolled in PARADIGM-HF and PARAGON-HF.","volume":"13","author":"Kondo","year":"2025","journal-title":"JACC Heart Fail"},{"issue":"12","key":"hoi260023r22","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.123.010898","article-title":"Efficacy of dapagliflozin according to heart rate: a patient-level pooled analysis of DAPA-HF and DELIVER.","volume":"16","author":"Kondo","year":"2023","journal-title":"Circ Heart Fail"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2847050\/jamacardiology_chimura_2026_oi_260023_1778624841.84446.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T15:01:39Z","timestamp":1778684499000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2847050"}},"subtitle":["A Prespecified Secondary Analysis of FINEARTS-HF"],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2026.1049","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}